Last reviewed · How we verify
BB-101
BB-101 is a small molecule that targets the PI3K pathway.
BB-101 is a small molecule that targets the PI3K pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | BB-101 |
|---|---|
| Sponsor | Blue Blood Biotech Corp. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BB-101 works by inhibiting the PI3K enzyme, which is involved in cell signaling and proliferation. This inhibition can lead to anti-tumor effects in various cancers.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers (PHASE2)
- BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BB-101 CI brief — competitive landscape report
- BB-101 updates RSS · CI watch RSS
- Blue Blood Biotech Corp. portfolio CI